Together with increase of proliferation potential, the myelodysplastic syndromes are characterised by qualitative abnormalities of differentiation of myeloid precursors associated with increased intramedullary apoptosis, resulting in peripheral cytopenia.
). We have compared bone marrow samples from 14 normal subjects (Table 1 ) and 40 patients with marked cytological bone marrow myelodysplasia (6 RA, 3 RARS, 1 5q-syndrome, 8 RAEB-1, and 5 RAEB-2, 4 AML with multilineage dysplasia classified as RAEB-T in the FAB classification and 13 patients with CMML). Using an extensive triple colour panel (Figure 1 ), we found that 90% of patients had at least one phenotypic abnormality, when compared to normal percentages of bone marrow sample (Table 1) . Cell subset identification was confirmed by gating on positive cells ( Figure 1A) . The three main phenotypic abnormalities were CD36 and CD117 on granulocytes, and abnormal expression of CD56 on monocytes (Table 1, Figure 1A and 1B), with a bimodal distribution, suggesting the phenotypic heterogeneity of bone marrow cells ( Figure 1A ). These results show that percentages are a valuable manner of expressing the results for at least three makers, CD36, CD117 on granulocytes and CD56 on monocytes of bone marrow in patients with myelodysplasia. From these bone marrow results, we defined a five color combination of antibodies: CD36FITC-CD117PE-CD45ECD-CD34Cy5-CD56Cy7 and tested it on 47 blood samples from patients with bone marrow dysplasia (16 RA, 5 RARS, 5 RAEB1, 8 RAEB2, 7 RAEBT, 6 CMML), nine of them with a comparison with the bone marrow. Results were compared to those of 30 normal blood samples and 30 blood samples from subjects with inflammatory monocytosis as a control. Thresholds of abnormal expression of CD117 and CD56 were higher in bone marrow than in blood, whereas they were comparable for CD36 (Table 1) . Abnormal expression of CD36 on granulocytes was more frequent in bone marrow than in blood ( Figure 1B ). CD117 expression was absent in circulating blood neutrophils in most patients with bone marrow dysplasia ( Figure 1B) . These results clearly suggest that blood is not the correct compartment to search for phenotypic abnormalities in myelodysplasia, and match with the very well-known fact that this disease resides mainly in the bone marrow, with in situ abortive myelopoiesis, resulting in a selection pressure against abnormal cells to reach peripheral blood. 3, 4 We found that expression of CD56 on monocytes was associated with CMML ( Figure 1A and 1B, p=0.03). CD56 expression was weak and very homogeneous on monocytes from normal blood samples, giving rise to a much lower threshold in blood than in bone marrow for this marker ( Figure 1B and Table 1 ). Like in bone marrow samples, a significant association between expression of CD56 and CMML was found in blood circulating monocytes (p=0.01 against normal subjects and patients with monocytosis, p=0.02 against other patients with myelodysplasia), despite a slight increase in CD56 expression on monocytes from blood samples in patients with inflammatory syndrome. Expression of CD56 on monocytes in patients with CMML has been recently reported.
5
The fact that CMML monocytes express CD56 is reminiscent of a rare disease: the CD4 + /CD56 + plasmacytoid leukemia. CMML is the unique neoplasm shown to possibly transform into CD4 + /CD56
+ plasmacytoid leukemia.
6
The recent WHO classification excludes chronic myelomonocytic leukemia (CMML) from myelodysplastic syndromes, putting it in a new mixed category termed myelodysplastic/myeloproliferative syndromes, to encourage further studies on this poorly understood disease.
7
According to both Rigolin et al. 8 and analysis of the series of our institution (unpublished), 20% of patients with myelodysplasia have an increased monocyte count. For Aul et al., CMML corresponds to 31% of patients with myelodysplasia.
9 CD56 on blood monocytes as a phenotypic abnormality in patients with CMML could provide a new and very simple tool for diagnosis and for further clinical and biological studies of this rather frequent yet not well understood disease.
Putting it all together, the data show that expressing flow cytometry results in percentages is valuable for myelodysplasia, that CD56 expression on monocytes is associated with CMML, and that, except for CD56, phenotypic aberrations are lost on blood cells.
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